Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.

BOSTON – At the AACR-NCI-EORTC Molecular Targets meeting in October, speakers in the second plenary session gave examples both of how far protein degradation has come as a pharmacological approach, and how far it could still go.

Year-to-date money raised in public, private and other financings of biopharma companies.

Arkuda Therapeutics, a new company targeting progranulin and lysosomal biology to treat neurodegenerative diseases, has completed a $44 million series A financing.

"Global approval doesn't mean Australia approval. Government needs a new way of valuing the benefit of therapies that are a one-off cure differently than other drugs."

President Donald Trump has officially nominated Stephen Hahn to the position of FDA commissioner, a position held on an interim basis by Ned Sharpless since April. Hahn has held the position of CEO of the MD Anderson Cancer Center in Houston since May 2018.

Therapeutic area data reported by biopharma companies on phase I trials in October 2019.

Therapeutic area data reported by biopharma companies on phase II trials in October 2019.

Therapeutic area data reported by biopharma companies on phase III trials in October 2019.

The top 10 biopharma stock gainers and losers for the week of Nov. 4-8, 2019.